Case Report

DOI: 10.5644/ama2006-124.248

TNS1-ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma

Jessica Lee¹, Arun Singh², Siraj M. Ali¹, Douglas I. Lin³, Samuel J. Klempner⁴,⁵

¹Foundation Medicine, Cambridge, MA, USA, ²Department of Medical Oncology, University of California Los Angeles, Los Angeles, CA, USA, ³Beth Israel Deaconess Medical Center, Boston, MA, USA, ⁴The Angeles Clinic and Research Institute, Los Angeles, CA, USA, ⁵Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Correspondence:
sklempner@theangelesclinic.org
Tel.: + 1 310 231 2167
Fax.: + 1 310 231 2172

Received: 16 September 2018
Accepted: 30 April 2019

Key Words: Alk • Leiomyosarcoma • IMT • Kinase Fusion • CGP.

Introduction

Leiomyosarcoma (LMS) is a malignant tumor arising from smooth muscle, typically of uterine origin (1). Management of disseminated or recurrent disease is challenging, with cytotoxic chemotherapy being the backbone of treatment despite poor outcomes with a median survival of 27 months from first disease recurrence (2). Diagnosis of LMS, especially of the myxoid type, may also be challenging since a subset of cases may be re-classified as either inflammatory myofibroblastic tumor (IMT) or high-grade endometrial stromal sarcoma (ESS) based on both morphologic, immunohistochemical and molecular features (3). Distinction of these entities may affect therapeutic decision-making as IMT and ESS may be less aggressive and more amenable to targeted therapies than LMS. Specifically, IMTs frequently harbor fusions of the ALK kinase that may be susceptible to ALK inhibitors, well established and approved agents in non-small cell lung cancer (4-6). A complementary role for molecular testing in advanced tumors is established, and comprehensive genomic profiling (CGP) has demonstrated ability to both re-classify tumors and distinguish recurrence from a second primary (7).

Here we present a case of a malignant and high stage uterine mesenchymal tumor, originally diagnosed as LMS, which after progression on LMS standard therapy was

Objective. We report a female patient diagnosed with a leiomyosarcoma and who harbored a druggable target as identified by comprehensive genomic profiling in the course of clinical care. Case Report. The patient progressed five years after curative intent surgery and adjuvant treatment. After failure of multiple lines of chemotherapy, she was enrolled in a trial of an ALK inhibitor based on comprehensive genomic profiling (CGP) identifying an TNS1-ALK fusion. Conclusion. In this case, identification of the ALK kinase fusion permitted enrollment in a matched mechanism driven clinical trial after exhausting standard of care treatment options. CGP raises the possibility of uterine inflammatory myofibroblastic tumor as an alternative diagnosis to leiomyosarcoma, highlighting the complementary role of CGP beyond immunohistochemical analyses.

Copyright © 2019 by the Academy of Sciences and Arts of Bosnia and Herzegovina.
found to harbor an ALK gene fusion by genomic profiling. This molecular finding enabled the patient to be enrolled in a clinical trial with the ALK-inhibitor crizotinib and suggested that the tumor was potentially a previously under-recognized IMT.

Methods

Comprehensive genomic profiling was performed on the Foundation One Heme panel (Foundation Medicine, Cambridge, MA, USA) in a CLIA certified laboratory. This method consists of the analysis of the coding DNA sequences of 405 cancer-related genes, selected introns of 31 genes involved in chromosomal rearrangements, and the RNA sequences of 265 genes commonly involved in fusions. The genes were sequenced to a median coverage of 859X and the sequences were analyzed for base substitutions, indels, copy number alterations, and rearrangements.

Case Presentation

A 39-year old African-American woman initially presented with a diagnosis of leiomyoma and ovarian cyst though concern for invasive disease remained. Therefore, a TAH-LSO was performed, and microscopic examination of the specimen identified a leiomyosarcoma. A completion BSO, omentectomy and tumor debulking was then performed, and LMS involving the omentum, right fallopian, and multiple colonic nodules was confirmed based on immunohistochemical and morphologic examination. She received six cycles of adjuvant gemcitabine and paclitaxel followed by radiation therapy. She was under surveillance with bi-annual imaging when a pelvic/bowel recurrence was identified 4 years from her original diagnosis. After surveillance imaging suspicious for recurrent disease, she underwent a PET-CT notable for a left pelvic mass superior to the bladder measuring 3.9cm with an SUV 10 and a cul de sac mass measuring 4.2 cm with an SUV of 5.3. She underwent a salvage partial colectomy and pathologic examination identified distal sigmoid colon and proximal rectal masses that were morphologically consistent with metastatic leiomyosarcoma. She was treated with palliative doxorubicin and olaratumab but imaging after the second cycle showed progression with an enlarging pelvis mass measures 5.8 x 5.6 cm with SUV 7.3, previously 2.9 x 3.1 cm with SUV 6.7. Two months after the third cycle of treatment, a pelvic mass was resected, which was again diagnosed as metastatic LMS and adherent to the small bowel serosa, without bowel wall involvement. A nodule on the sigmoid colon was also interpreted as LMS. Two months after surgery, adjuvant pazopanib at 400 mgs daily was initiated, and then switched to 400/600 mg alternating daily due to poor tolerance and fatigue.

After 12 months on pazopanib she presented to an emergency room with pain and was found to have progressive disease. She was transitioned to trabectedin but tolerated it poorly, and imaging after two cycles confirmed further disease progression. In an effort to explore all possible treatment options a specimen from the salvage colectomy was sent for comprehensive genomic profiling as previously described (8). CGP identified a predicted oncogenic TNS1-ALK fusion which was also observed in a complementary circulating tumor DNA assay (Figure 1). Based on her CGP results she was screened for a precision medicine clinical trial (NCT02693535). Owing to impaired renal function from extrinsic compression by the large pelvic mass (Figure 1A) she was deemed ineligible. In the absence of ability to get on trial she was transitioned to Brigatinib off-label. Within 2 weeks she had significant improvement in pain and was able to come off all opioids. First imaging re-
revealed radiographic partial response (Figure 1B) which has continued for 9 months at the time of submission. There were no adverse events on Brigatinib 180 mg once daily.

**Discussion**

Morphologic and immunohistochemical (IHC) analyses remain important tools in classifying solid tumors, but can be complicated by inter-observer variability, overlapping IHC and morphology in rare tumors. Molecular testing is a complementary tool, capable of both identifying pathognomonic molecular alterations that aid in diagnosis while simultaneously exploring rare variants that exist across tumor types. The case presented here supports the clinical utility of CGP in advanced, recurrent, and refractory cancers.

Recent work has demonstrated that inflammatory myofibroblastic tumor (IMT) is strongly associated with kinase fusions, particularly ALK fusions (9, 10). Notably, IMTs often arise in the uterus, and as such can be...
misdiagnosed as leiomyosarcoma, particularly the myxoid variety (11). A case reported previously had such myxoid features and was diagnosed as a smooth muscle tumor of uncertain malignant potential, but harbored an ALK fusion and was ultimately revised to a diagnosis of uterine IMT (12). In a large series of myxoid LMS, 4 of 30 cases (13%) were potentially under-recognized IMT based on either ALK positivity by immunohistochemistry or ALK gene rearrangements (3). The diagnosis of each is based on morphologic and immunohistochemical characteristics, but the identification of an ALK fusion/rearrangement may greatly aid in the diagnosis of difficult cases. Indeed, after re-review of morphology of available H&E image and molecular profile, this particular tumor may be best re-classified as an IMT. At present, there are multiple reports of uterine IMT patients who harbor an ALK fusion and who have responded to an ALK inhibitor (10, 13, 14). Molecular profiling of recurrent, metastatic uterine mesenchymal tumors may potentially aid in the diagnosis of difficult cases and enable patient enrollment in appropriate clinical trials. Owing to the rare nature of LMS and other uterine sarcomas compounded by the relative rarity of actionable alterations, randomized prospective trials are unlikely to be completed. Multi-arm basket trials matching treatments to genomic alterations, such as the ASCO TAPUR study, may be the optimal mechanism for prospective efficacy assessment as was done for this patient.

Conclusion

Identification of the TNS1-ALK fusion through CGP allowed for this tumor, originally diagnosed as LMS, to be recharacterized as an IMT. The patient also benefitted from targeted therapy, which highlights the dual role that genomic profiling can play in aiding with classifying diagnostically challenging cases and enabling patients to benefit from matched targeted therapy typically within a mechanism driven clinical trial.

What Is Already Known on this Topic

Diagnosis of leiomyosarcoma based off morphologic and immunohistochemical characteristics can be challenging and a number of cases may be reclassified as IMTs as IMTs frequently harbor kinase fusions, particularly those of ALK, which can also allow for treatment with matched targeted therapy.

What this Study Adds

We report a patient with a tumor originally diagnosed as LMS that failed multiple lines of chemoradiation. CGP revealed that the tumor harbored a TNS1-ALK fusion that led to the revision of the patient’s diagnosis to uterine IMT and subsequent enrollment in an ALK inhibitor trial.

Authors’ Contributions: Conception and design: SMA and SJK; Acquisition, analysis, and interpretation of data: JL, AS, SMA, DIL and SJK; Drafting the article: SMA and JL; Revising it critically for important intellectual content: SMA, JL and SJK; Approved final version of the manuscript: JL, AS, SMA, DIL and SJK.

Conflict of Interest: JL, DIL, and SMA are employees of and have equity interest in Foundation Medicine, a wholly owned subsidiary of Roche Pharmaceuticals. SMA serves on the SAB of Incysus Inc., and consulting with Revolution Medicines and Takeda (non-oncology). AS declares honoraria/consultant fees from Eli Lilly, Novartis, Daiichi Sankyo, and serves on the Board of Directors for Certis Oncology Solutions. SJK declares honoraria from Foundation Medicine, Inc., and consultant/advisory fees from Eli Lilly, Astellas, Boston Biomedical, and has ownership/equity in TP Therapeutics.

References